We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.23% | 29.75 | 29.55 | 30.50 | 30.05 | 29.53 | 29.80 | 5,444,214 | 21:57:01 |
From May 2019 to May 2024
By Cecilia Butini
France's antitrust authority said Wednesday it has fined pharmaceutical companies Novartis AG, Roche Holding AG and Genentech a total of 444 million euros ($552.8 million) for abusive practices related to the marketing of an eye-disease treatment.
The authority said the three companies abused their collective dominant position with respect to the sales of Lucentis, a drug developed by Genentech laboratories to treat age-related macular degeneration, a condition which causes low vision in people over 50.
According to the French authority, the three companies' practices were aimed at curbing the use of another equally effective drug, Avastin, which cost 30 times less than Lucentis.
The EUR444 million fine comprises a EUR385.1 million penalty for Novartis and EUR59.7 million for Roche and Genentech, the competition authority said. Genentech is a subsidiary of Roche.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
September 09, 2020 06:54 ET (10:54 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
